Results 121 to 130 of about 8,055 (251)

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

Cardiorenal Mortality and Safety Outcomes of GLP‐1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiorenal evidence for glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/m2 are limited. Materials and Methods We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to ...
Shao‐Chia Chen, Yu‐Nan Huang, Pei‐Yun Li, Jo‐Ching Chen, Gideon Meyerowitz‐Katz, Shun‐Fa Yang, Pen‐Hua Su   +6 more
wiley   +1 more source

Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review [PDF]

Objective: This review examines tirzepatide, a GLP-1 agonist, to treat liver diseases like nonalcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH).
Bryan, Carina, Kahook, Zaneh, Parmar, Mayur S, Jones, Talaya   +3 more
core   +1 more source

Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide

Tirzepatide is a long-acting agonist for the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors approved for the treatment of type 2 diabetes mellitus, weight management in obese patients, or overweight patients with at ...
Wici\u144ski, Micha\u142, Justyna Jaraczewska, Rzepi\u144ski, \u141ukasz, Al-Shaer, Aysheh, Michał Wiciński, Anna Tywoniuk, Jaraczewska, Justyna, Aysheh Al-Shaer, Tywoniuk, Anna, Łukasz Rzepiński   +9 more
core   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST‐T1D Extension Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial. Materials and Methods Continuous glucose monitoring (CGM) data were collected during a 12‐week extension phase after the ADJUST‐T1D trial.
Eslam Montaser, Kanchan Bhasin, Davida Kruger, Halis Kaan Akturk, Andrew Ahmann, Janet K. Snell‐Bergeon, Viral N. Shah   +6 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source

Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes

Background: The comparative gastrointestinal safety across glucagon-like peptide-1 receptor agonists and tirzepatide is still unclear. Objective: To compare the risk for severe gastrointestinal adverse events across dulaglutide, subcutaneous semaglutide,
Glynn, Robert J, Alkabbani, Wajd, Paik, Julie M, Wexler, Deborah J, Patorno, Elisabetta, Crisafulli, Salvatore, Yu, Elaine W, Trifirò, Gianluca, Bykov, Katsiaryna, Tavakkoli, Ali, Htoo, Phyo T   +10 more
core   +1 more source

GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial: Rationale, Design and Baseline Characteristics

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims No studies have investigated the synergistic effectiveness of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1RAs) in patients with persistent obesity following bariatric surgery. The GLP‐1 Receptor Agonists Post‐Bariatric Surgery (GRABS) Trial aims to investigate the effectiveness of tirzepatide (TRZ) versus standard of care (SOC) after ...
J. M. Samuels, C. R. Williams, M. B. Patel, W. H. Self, L. M. Funk, C. Roumie, M. D. Spann, C. J. Northup, F. Ye, R. Irlmeier, I. Sohn, Y. Zhu, K. Niswender   +12 more
wiley   +1 more source

Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP‐1 Receptor Agonist Claims

Diabetes, Obesity and Metabolism, EarlyView.
Matthew J. Klebanoff, John C. Lin, Judith A. Long, Eric Bressman, Jalpa A. Doshi   +4 more
wiley   +1 more source